Title:
ＣＤＫ阻害剤と関連するバイオマーカー
Document Type and Number:
Japanese Patent JP6387001
Kind Code:
B2
Abstract:
The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Cyclin Dependent kinase inhibitors (CDKi), methods of determining the sensitivity of a cell to a CDKi, methods of treating a patient with a CDKi and methods of screening for candidate CDKi.
Inventors:
Caponigro, Giordano
Deluxe, scott
Galaway, Levi
Jagan, Zainab
Kim, Sunkyu
Krykov, Gregory
Deluxe, scott
Galaway, Levi
Jagan, Zainab
Kim, Sunkyu
Krykov, Gregory
Application Number:
JP2015521641A
Publication Date:
September 05, 2018
Filing Date:
June 26, 2013
Export Citation:
Assignee:
Novartis Age
Dana Faber Cancer Institute, Incorporated
Broad Institute
Dana Faber Cancer Institute, Incorporated
Broad Institute
International Classes:
C12Q1/48; A61K31/454; A61K45/00; A61P35/00; C12Q1/04; C12Q1/6827; C12Q1/6886; G01N33/15; G01N33/50; G01N33/68
Foreign References:
| US20110151469 | ||||
| US20110009353 |
Other References:
Pasqualucci, L., et al.,Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma,Nature Genetics,2011年,Vol.43, No.9,pp.830-837
Attorney, Agent or Firm:
Hiroshi Kobayashi
Norio Omori
Emiko Nishizawa
Yasuhito Suzuki
Norio Omori
Emiko Nishizawa
Yasuhito Suzuki
Previous Patent: Ｎ−置換スルホキシイミン・ピリジンＮ−オキシドの製造
Next Patent: TRANSMISSION/RECEPTION ANTENNA FOR SATELLITE BROADCAST
Next Patent: TRANSMISSION/RECEPTION ANTENNA FOR SATELLITE BROADCAST